Thursday, March 10, 2011

MS Society of Canada - News in Research
On March 9, 2011, Health Canada approved Gilenya™ (fingolimod) capsules, the first oral disease-modifying therapy developed for relapsing-remitting MS.
Gilenya (prounounced Jil-EN-ee-ah) has been approved for use in people who have tried one or more MS therapies, but are unresponsive or intolerant to them. It is indicated for use as a monotherapy for the treatment of people with the relapsing-remitting form of MS to reduce the frequency of clinical exacerbations (relapses) and to delay the progression of physical disability. Health Canada’s approval is based on results from two large-scale placebo-controlled clinical trials, each with over 1,200 participants.
Gilenya is a new class of medication called a sphingosine 1-phosphate receptor modulator, which is believed to act by retaining certain white blood cells (lymphocytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to the nerve cells.
Details
The medication will be available in Canadian pharmacies by...Read More

Bookmark and Share